대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Network Pharmacology and in Vitro Experimental Verification Reveal the Mechanism of Hederagenin in Suppressing Podocyte Injury in Focal Segmental Glomerular Sclerosis
저자	Hu Qiongdan
출판정보	2024; 2024(1):
키워드
초록	Objectives: Podocyte injury in FSGS is a complex process in chronic kidney disease (CKD). Hederagenin (HDG) shows potential for treating CKD but its role in FSGS-induced podocyte injury and its characteristics need further elucidation. Methods: In this study, researchers identified targets of HDG and FSGS from Genecards database. A drug-disease network revealed the relationship between HDG, FSGS, and their targets. Mechanism of HDG on FSGS was confirmed through molecular docking. In vitro experiments on MPC5 cell line verified HDG’s inhibitory effect on podocyte injury in FSGS. Results: Our systematic analysis via the protein-protein interaction (PPI) network revealed the potential mechanisms of HDG in treating FSGS. Consequently, we extracted two therapeutic targets strongly related to FSGS; IL-6 and NOS2, which were found to be bound to HDG via molecular docking, providing the basis for its inhibitory effect on FSGS. Additionally, our in vitro experiments demonstrated that HDG could alleviate TGF-β1-induced injury in MPC5 cells, and significantly reduce the mRNA and protein levels of IL-6 and NOS2.The above research workflow is shown in Figure 1. Conclusions: This study utilized network pharmacology along with experimental validation to promote the application of HDG in FSGS and to interpret and understand the molecular biological mechanisms involved.
원문(PDF)	PDF 원문보기

목록

위로가기